ATE507296T1 - Verwendung von fibroblasten-wachstumsfaktor- fragmenten - Google Patents

Verwendung von fibroblasten-wachstumsfaktor- fragmenten

Info

Publication number
ATE507296T1
ATE507296T1 AT04797676T AT04797676T ATE507296T1 AT E507296 T1 ATE507296 T1 AT E507296T1 AT 04797676 T AT04797676 T AT 04797676T AT 04797676 T AT04797676 T AT 04797676T AT E507296 T1 ATE507296 T1 AT E507296T1
Authority
AT
Austria
Prior art keywords
fgf
discovery process
organism
growth factor
administration
Prior art date
Application number
AT04797676T
Other languages
English (en)
Inventor
Jacques Bollekens
Salah-Dine Chibout
Jacky Vonderscher
Francois Legay
Andre Cordier
Ruben Papoian
Andreas Scherer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE507296T1 publication Critical patent/ATE507296T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Primary Health Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
AT04797676T 2003-11-07 2004-11-05 Verwendung von fibroblasten-wachstumsfaktor- fragmenten ATE507296T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51807303P 2003-11-07 2003-11-07
US57224704P 2004-05-18 2004-05-18
PCT/EP2004/012572 WO2005045044A2 (en) 2003-11-07 2004-11-05 Use of fibroblast growth factor fragments

Publications (1)

Publication Number Publication Date
ATE507296T1 true ATE507296T1 (de) 2011-05-15

Family

ID=34576820

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04797676T ATE507296T1 (de) 2003-11-07 2004-11-05 Verwendung von fibroblasten-wachstumsfaktor- fragmenten

Country Status (7)

Country Link
US (3) US20090093398A1 (de)
EP (1) EP1682665B1 (de)
JP (1) JP5118851B2 (de)
AT (1) ATE507296T1 (de)
DE (1) DE602004032457D1 (de)
ES (1) ES2365852T3 (de)
WO (1) WO2005045044A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
JP2006347979A (ja) * 2005-06-17 2006-12-28 National Institute Of Advanced Industrial & Technology 創傷治療及び／又は創傷治癒促進のための薬剤
EP1864692A1 (de) * 2006-06-07 2007-12-12 Biotempt B.V. Verwendung von peptiden zum Schutz von Strahlenschäden
US11308462B2 (en) 2014-05-13 2022-04-19 Clear Token Inc Secure electronic payment
WO2016208776A1 (ja) 2015-06-25 2016-12-29 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
JP6332780B2 (ja) 2016-03-29 2018-05-30 株式会社国際電気通信基礎技術研究所 医薬組成物又は食品組成物、及び有効成分の体内での効果の評価方法
CN114594268A (zh) 2016-03-29 2022-06-07 无限生物制药公司 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法
US20230025003A1 (en) * 2019-10-18 2023-01-26 BioZipcode, Inc. Diabetes therapy targeting abnormal stem cells
US20230382966A1 (en) * 2020-10-27 2023-11-30 Indiana University Research And Technology Corporation Novel klotho interaction site in the c-terminus of fgf23
CN114940990B (zh) * 2022-06-20 2023-03-14 北京市神经外科研究所 与颅内动脉瘤相关的基因突变位点及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066595A2 (en) * 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
AU2001245535A1 (en) * 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
JP2004504063A (ja) * 2000-07-19 2004-02-12 アドバンスド　リサーチ　＆　テクノロジー　インスティテュート 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法
EP1343006A4 (de) * 2000-11-15 2007-06-06 Akiko Itai Verfahren zur charakterisierung von proteinen
JP2002223753A (ja) * 2001-01-30 2002-08-13 Hitachi Ltd 薬物応答解析用オリゴヌクレオチドアレイ
WO2002088358A2 (en) * 2001-04-26 2002-11-07 Geneprot, Inc. Human fibroblast growth factor-related compositions
WO2003083110A1 (en) * 2002-03-29 2003-10-09 National Institute Of Advanced Industrial Science And Technology Novel galactose transferases, peptides thereof and nucleic acid encoding the same
JPWO2003091427A1 (ja) * 2002-04-24 2005-09-02 関西ティー・エル・オー株式会社 近位尿細管に発現する腎疾患関連遺伝子群

Also Published As

Publication number Publication date
JP5118851B2 (ja) 2013-01-16
WO2005045044A3 (en) 2005-11-10
DE602004032457D1 (de) 2011-06-09
US20120028896A1 (en) 2012-02-02
HK1095160A1 (en) 2007-04-27
EP1682665A2 (de) 2006-07-26
JP2007521799A (ja) 2007-08-09
US20130040882A1 (en) 2013-02-14
EP1682665B1 (de) 2011-04-27
US20090093398A1 (en) 2009-04-09
WO2005045044A2 (en) 2005-05-19
ES2365852T3 (es) 2011-10-11

Similar Documents

Publication Publication Date Title
Eigenbrod et al. Rapid molecular evolution of pain insensitivity in multiple African rodents
Hallböök et al. Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in Xenopus ovary
DE602004032457D1 (de) Nten
Guddat et al. Three-dimensional structure of the α-conotoxin GI at 1.2 Å resolution
Lucas et al. Mapping the lectin-like activity of tumor necrosis factor
Tollis et al. Comparative genomics reveals accelerated evolution in conserved pathways during the diversification of anole lizards
Ushach et al. METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages
Parsons et al. Roles for Bmp4 and CaM1 in shaping the jaw: evo-devo and beyond
Holford et al. Pruning nature: Biodiversity-derived discovery of novel sodium channel blocking conotoxins from Conus bullatus
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
Tettamanti et al. Phylogenesis of brain-derived neurotrophic factor (BDNF)‏ in vertebrates
Pan et al. Isolation and characterization of myrmexins, six isoforms of venom proteins with anti-inflammatory activity from the tropical ant, Pseudomyrmex triplarinus
Suire et al. Peptidic inhibitors of insulin-degrading enzyme with potential for dermatological applications discovered via phage display
Neves et al. Characterization of the first conotoxin from Conus ateralbus, a vermivorous cone snail from the Cabo Verde archipelago
Zocchi et al. Deciphering the tubulin language: Molecular determinants and readout mechanisms of the tubulin code in neurons
Goodchild et al. Maps of cardiovascular and respiratory regions of rat ventral medulla: focus on the caudal medulla
BRPI0406680A (pt) Métodos para selecionar um animal para ter propriedades desejadas genotìpicas ou fenotìpicas em potencial, para modular a trascrição de mrna de um gene igf2 em uma célula ou organismo provido com referido gene e para identificar um composto, composto, composição farmacêutica, e, uso de um composto
Stauch et al. Quantitative proteomics of presynaptic mitochondria reveal an overexpression and biological relevance of neuronal MitoNEET in postnatal brain development
de Araujo et al. Do vicinal disulfide bridges mediate functionally important redox transformations in proteins?
CN1051182A (zh) 用作钙通路阻滞剂的多肽
Pandya et al. Integrative temporo-spatial, mineralogic, spectroscopic, and proteomic analysis of postnatal enamel development in teeth with limited growth
Chen et al. Analysis of mitochondrial DNA polymorphisms in Guangdong Han Chinese
Boutin et al. MCH-R1 antagonist GPS18169, a pseudopeptide, is a peripheral anti-obesity agent in mice
Valenzuela et al. Alternative splicing mechanisms for the modulation of protein function: conservation between human and other species
CN106957359A (zh) Fgf1突变体及其医药应用

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties